Finding Cancer First: Early Detection Saves Lives
Early detection is critical for improving cancer treatment outcomes, and CeMines is leading the way with groundbreaking diagnostic solutions.
At CeMines, we are developing a next-generation, cost-effective cancer diagnostic technology that provides accurate and early detection through a simple blood test. By focusing on cell-specific regulatory mechanisms and cancer-associated biomarkers, we enable faster, more precise diagnoses, especially for high-risk populations.
Company Overview
Founded in 2000, CeMines is at the forefront of cancer diagnostics, using advanced methods like auto-antibody detection and splice variant analysis. Our approach focuses on identifying cancer-specific antibodies in blood samples, allowing for early diagnosis, often before the disease progresses.
While our primary focus is on lung cancer, our innovative diagnostic methods also extend to breast, gastrointestinal cancers, leukemia, and immune disorders, including Hepatitis C, HIV, and Rheumatoid Arthritis.
CeMines’ headquarters are in Golden, Colorado, with scientific laboratories located in Tallinn, Estonia.
Innovative Multi-Biomarker Approach to Diagnostics :
CeMines enhances cancer detection accuracy through a unique multi-biomarker approach that integrates statistical analysis of several biomarkers, boosting the sensitivity and reliability of results. Our technology uses alternative mRNA splice variants and cancer-specific antibodies produced by the immune system to identify the presence of cancer, offering a more precise diagnostic tool than conventional methods.
Why Choose CeMines Diagnostics?
Our Mission
At CeMines, our mission is clear: harness innovative science to provide early cancer detection, improve healthcare outcomes, and contribute to global health advancements. Together, our experienced team of leaders and researchers drives this mission forward with a commitment to excellence and innovation.
